Rifamycin antibiotics and the mechanisms of their failure.

TitleRifamycin antibiotics and the mechanisms of their failure.
Publication TypeJournal Article
Year of Publication2021
AuthorsAdams, RA, Leon, G, Miller, NM, Reyes, SP, Thantrong, CH, Thokkadam, AM, Lemma, AS, Sivaloganathan, DM, Wan, X, Brynildsen, MP
JournalJ Antibiot (Tokyo)
Date Published2021 Nov
KeywordsAnimals, Antibiotics, Antitubercular, Drug Resistance, Microbial, Humans, Mycobacterium tuberculosis, Rifamycins, Treatment Failure, Tuberculosis

<p>Rifamycins are a class of antibiotics that were first discovered in 1957 and are known for their use in treating tuberculosis (TB). Rifamycins exhibit bactericidal activity against many Gram-positive and Gram-negative bacteria by inhibiting RNA polymerase (RNAP); however, resistance is prevalent and the mechanisms range from primary target modification and antibiotic inactivation to cytoplasmic exclusion. Further, phenotypic resistance, in which only a subpopulation of bacteria grow in concentrations exceeding their minimum inhibitory concentration, and tolerance, which is characterized by reduced rates of bacterial cell death, have been identified as additional causes of rifamycin failure. Here we summarize current understanding and recent developments regarding this critical antibiotic class.</p>

Alternate JournalJ Antibiot (Tokyo)
PubMed ID34400805
PubMed Central ID4930915